Autoimmune Heart Disease: Symptoms, Causes & Treatment

Autoimmune heart disease is not a single condition but a family of disorders in which the immune system attacks the heart’s own tissue, potentially damaging the muscle, valves, lining, or blood vessels that supply them. The whole structure of the heart can be affected, causing problems that range from subtle rhythm disturbances to sudden heart failure in people who seemed perfectly healthy days earlier.¹ Because the symptoms often look like those of other heart problems, autoimmune forms are easy to miss and sometimes only identified after serious damage has already occurred.²

How the Immune System Turns on the Heart

Under normal circumstances, the immune system learns early in life to recognize the body’s own proteins as “self” and leave them alone. In autoimmune heart disease, that tolerance breaks down. Immune cells or antibodies begin targeting proteins found in heart muscle, valve tissue, or the sac surrounding the heart. One of the best-understood triggers is molecular mimicry: a foreign invader, often a bacterium or virus, carries surface proteins that closely resemble proteins in the heart. The immune system mounts an attack against the invader and, in the process, starts cross-reacting with cardiac tissue.

Rheumatic heart disease is the textbook example. Group A streptococcus bacteria carry molecules that structurally resemble cardiac myosin, the main contractile protein in heart muscle. After a strep throat infection, the immune response sometimes locks onto those look-alike heart proteins and begins damaging the valves.³ Immune T cells then migrate from the bloodstream into the heart valves, where they multiply and sustain the attack. An imbalance of inflammatory signals in the valve tissue drives progressive, permanent damage.⁴

The mimicry concept extends beyond strep infections. In autoimmune myocarditis, antibodies against cardiac myosin have been found to also latch onto the beta-adrenergic receptor on heart cells, which is one of the key receptors that regulates how fast and hard the heart beats. When antibodies bind that receptor, they can trigger abnormal signaling inside the cell, essentially sending the heart muscle false instructions.⁵

Genetic Susceptibility

Not everyone who gets a strep infection or a viral illness goes on to develop autoimmune heart disease. Part of the explanation is genetic. A group of genes known as HLA (human leukocyte antigen) genes play a central role in deciding which bits of protein the immune system “sees” and responds to. Certain HLA variants are linked to higher risk of myocarditis and its downstream complication, dilated cardiomyopathy. These variants influence how well the body clears viruses, how prone the immune system is to cross-reacting with cardiac proteins, and how aggressively inflammatory signals ramp up.⁶ In practical terms, this means autoimmune heart disease tends to cluster in families, though the pattern is not as simple as inheriting a single gene. The genetic picture looks more like a collection of small predispositions that, combined with the right environmental trigger, tip the immune system toward self-attack.

Symptoms to Watch For

One of the frustrating aspects of autoimmune heart disease is how nonspecific the early symptoms can be. The presentation depends on which structure is under attack and how quickly the damage accumulates. Here are the main symptom patterns, grouped by the part of the heart involved:

Myocarditis (muscle): Fatigue, chest pain, shortness of breath, rapid or irregular heartbeat, and sometimes flu-like symptoms in the days or weeks before heart problems appear. In severe cases, fainting or sudden cardiac arrest can be the first sign.
Pericarditis (outer sac): Sharp chest pain that tends to worsen when lying flat or taking a deep breath, low-grade fever, and a general sense of being unwell. Pain often improves when sitting up and leaning forward.
Valvular damage: A new heart murmur, increasing shortness of breath with exertion, swollen ankles, and fatigue that worsens over months to years. In conditions like rheumatic heart disease or lupus-related valve disease, these symptoms build gradually.
Conduction abnormalities: Dizziness, palpitations, episodes of nearly blacking out, or an unusually slow heart rate. These can appear when inflammation disrupts the heart’s electrical wiring.

Many of these symptoms overlap with common, less serious conditions like viral infections, anxiety, or deconditioning. The red flags that should push someone toward urgent evaluation are chest pain combined with a recent illness, new unexplained heart failure symptoms in a younger person, or new rhythm disturbances that do not have an obvious cause. Cardiac changes in autoimmune disease can lead to fatal outcomes in young, seemingly healthy people when the condition goes unrecognized.²

The Major Autoimmune Conditions That Target the Heart

Rheumatic Heart Disease

Rheumatic heart disease remains one of the most common forms of autoimmune cardiac damage worldwide, particularly in low- and middle-income countries where strep infections are undertreated. The disease predominantly affects the mitral valve and is characterized by progressive fibrotic thickening.⁷ What makes rheumatic heart disease particularly insidious is that it keeps getting worse even after the initial inflammation quiets down. The altered shape of the damaged valve creates abnormal blood flow patterns that place ongoing mechanical stress on the tissue, which activates scarring cells and remodels the valve even further, independent of the original immune attack.⁷

Autoimmune Myocarditis and Dilated Cardiomyopathy

Autoimmune myocarditis is inflammation of the heart muscle driven by the body’s own immune cells. In many cases it begins after a viral infection and then takes on a life of its own as the immune response shifts from attacking the virus to attacking cardiac proteins. This condition frequently affects children and young adults and can progress to dilated cardiomyopathy, a state in which the heart muscle weakens and the chambers enlarge, reducing the heart’s ability to pump effectively.⁸ During the chronic phase, extensive scarring of the muscle leads to thinning of the ventricular walls and declining function.⁹ The transition from acute inflammation to chronic heart failure is not inevitable, but it remains difficult to predict who will recover and who will not.

Giant Cell Myocarditis

Giant cell myocarditis is rare but aggressive. It typically strikes previously healthy adults and progresses rapidly, often presenting with heart failure, dangerous rhythm disturbances, or complete heart block. Without treatment, the median survival is about three months from the time of diagnosis to either death or the need for a heart transplant.¹⁰ The disease is driven by T-cell lymphocytes that infiltrate and destroy heart muscle, and it demands urgent recognition because early immunosuppressive treatment can meaningfully extend survival.¹¹

Lupus-Related Heart Disease

Systemic lupus erythematosus can affect every layer of the heart. The most well-known cardiac complication is pericarditis, but lupus also causes a distinctive valve condition called Libman-Sacks endocarditis, in which sterile growths develop on the heart valves, most often the mitral and aortic valves.¹² In one study of 342 lupus patients, about 11% had these valve growths, and nearly two-thirds of those cases involved the mitral valve. The condition was strongly associated with longer disease duration, higher disease activity, and the presence of antiphospholipid antibodies.¹³ Antiphospholipid syndrome, whether occurring alongside lupus or on its own, carries a particular cardiac risk: about 30% of patients develop valve disease, and the condition worsens over time with an increased stroke risk.¹⁴

Rheumatoid Arthritis and the Heart

The heart complications of rheumatoid arthritis extend well beyond joint pain. People with RA face elevated rates of pericarditis, myocarditis, valve disease, and a form of heart damage caused by amyloid protein deposits. But the bigger-picture concern is accelerated coronary artery disease and congestive heart failure, which occur more frequently in RA patients than in the general population and are a leading cause of the increased mortality that comes with the disease.¹⁵ Chronic systemic inflammation appears to drive atherosclerosis faster, independent of traditional risk factors like high cholesterol or smoking.

How Autoimmune Heart Disease Is Diagnosed

Diagnosis is often a process of elimination, pieced together from blood work, imaging, and sometimes a tissue sample. Routine tests like an electrocardiogram and echocardiogram may show abnormalities, but they rarely point to an autoimmune cause on their own. Cardiac MRI has become an increasingly important tool because it can detect subtle patterns of inflammation and scarring in the heart muscle that other imaging misses, making it especially useful for confirming myocarditis.¹⁶

Blood tests for cardiac-specific autoantibodies can support a diagnosis, particularly when the clinical picture is ambiguous. In one study, the detection of these antibodies helped identify autoimmune involvement in a subset of patients with myocarditis, and the antibody findings did not always match what a traditional heart-muscle biopsy showed. This suggests that relying on biopsy alone can miss cases where the immune system is clearly part of the problem.¹⁷ Endomyocardial biopsy, where a tiny sample of heart tissue is taken through a catheter, remains the gold standard for certain conditions like giant cell myocarditis, where seeing the characteristic immune cells under a microscope confirms the diagnosis. However, it is an invasive procedure, carries some risk, and can produce misleading results if the sample is taken from an area the disease has not yet reached.

In practice, most clinicians piece the diagnosis together by combining blood markers of inflammation and heart injury, imaging findings, the patient’s underlying autoimmune conditions, and sometimes the response to immunosuppressive treatment itself. Modern imaging picks up cardiac abnormalities in most systemic inflammatory diseases, though how much clinical significance those findings carry is not always clear.¹⁸

Treatment Approaches

Treatment for autoimmune heart disease generally runs on two parallel tracks: managing the heart failure itself and trying to calm down the immune attack driving the damage. The heart-failure side uses standard medications including diuretics, ACE inhibitors, and beta-blockers.¹⁹ These drugs reduce the workload on a struggling heart, control fluid buildup, and help stabilize rhythm problems. They are the backbone of care regardless of whether the underlying cause is autoimmune, viral, or something else entirely.

The immunosuppressive side is where things get complicated. For garden-variety autoimmune myocarditis, the evidence for routine immunosuppression is mixed. The only randomized trial specifically testing steroids combined with either cyclosporine or azathioprine in biopsy-confirmed myocarditis found no significant improvement in survival compared with standard heart-failure therapy alone.²⁰ However, a broader look across three decades of research using both prospective and retrospective data paints a slightly more encouraging picture: pooled results from retrospective studies showed a survival benefit favoring immunosuppression, and there was a trend toward improved heart-pumping function in the treated groups, though it did not reach statistical certainty in the prospective trials.²¹

Giant cell myocarditis is the exception where immunosuppression is clearly warranted and can be life-saving. Given the disease’s otherwise rapid progression, aggressive treatment with combinations of corticosteroids and other immune-suppressing agents is standard practice. For conditions like cardiac sarcoidosis, which involves granulomatous inflammation of the heart, targeted therapies are being explored. In a small single-center study, rituximab, a drug that depletes a specific type of immune cell, reduced cardiac inflammation in six of seven patients with sarcoidosis that had not responded to conventional treatment.²² Results like these are preliminary but suggest there are options for patients who do not respond to first-line drugs.

Checkpoint Inhibitor Myocarditis, an Emerging Problem

Cancer immunotherapy has created an entirely new category of autoimmune heart disease. Immune checkpoint inhibitors, drugs that unleash the immune system to fight tumors, can accidentally unleash it against the heart as well. This form of myocarditis is uncommon but dangerous, typically appearing within the first few weeks of starting treatment.²³ The clinical picture can be deceptive: nearly half of patients show no decline in the heart’s pumping ability on an echocardiogram, yet many develop life-threatening arrhythmias, conduction blocks, or sudden cardiac death. Severe cases often involve simultaneous inflammation of skeletal muscles and sometimes the neuromuscular junction, creating a multi-organ crisis.²⁴

Research in animal models has shown that blocking the PD-1 checkpoint pathway leads to a significant increase in immune cells that specifically recognize cardiac myosin within the heart, providing direct evidence that checkpoint inhibition can awaken dormant self-reactivity against the heart.²⁵ For oncologists and cardiologists alike, this has made cardiac monitoring a routine part of checkpoint inhibitor therapy. The standard response when myocarditis is detected is to stop the immunotherapy and start high-dose corticosteroids, though some patients require additional immunosuppression.

Neonatal Lupus and Congenital Heart Block

Autoimmune heart disease does not always start in the patient’s own immune system. In neonatal lupus, antibodies from a mother with lupus or a related autoimmune condition cross the placenta and attack the developing fetal heart. The most serious consequence is congenital heart block, in which the electrical signal that coordinates heartbeats is permanently disrupted. This is actually the most common cause of congenital heart block overall.²⁶ The condition is typically detected when a routine prenatal ultrasound reveals an abnormally slow fetal heart rate. Many affected babies ultimately need a permanent pacemaker. The mother may not even have a lupus diagnosis at the time; sometimes the pregnancy complication is what leads to her own evaluation for autoimmune disease.

Pregnancy and Cardiovascular Risk in Autoimmune Disease

Beyond the specific issue of neonatal lupus, pregnancy itself carries heightened cardiovascular risk for anyone with an autoimmune or rheumatic disease. A large study comparing pregnancy outcomes found that cardiovascular events occurred in about 1.4% of pregnancies in women with autoimmune and rheumatic diseases, compared with 0.3% of pregnancies in women without these conditions. Among women with primary antiphospholipid syndrome, the rate was even higher at roughly 5.5%. When cardiovascular events did occur during pregnancy, they were associated with substantially greater rates of complications including preterm birth and smaller-than-expected babies.²⁷ For women with these conditions, preconception planning with both a rheumatologist and a cardiologist can help identify and manage risks before they become emergencies.

Vasculitis and Accelerated Heart Risk

Small-vessel vasculitis, particularly a group of conditions called ANCA-associated vasculitis, can damage the heart through a less obvious route. Rather than direct immune attack on heart tissue, the chronic inflammation these conditions produce accelerates atherosclerosis, the process of plaque buildup in coronary arteries. A meta-analysis found that patients with ANCA-associated vasculitis face a roughly 65% higher risk of cardiovascular events compared with the general population, with elevated rates of heart attack and stroke that appear independent of conventional risk factors like cholesterol or blood pressure.²⁸ The risk is highest in the first year after diagnosis, which has implications for how aggressively these patients should be screened and treated for cardiovascular disease from the outset.

1
PubMed Central. Cardiac damage in autoimmune diseases: Target organ involvement that cannot be ignored
2
PubMed Central. Autoimmune Heart Disease: A Comprehensive Summary for Forensic Practice
3
PubMed. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease
4
PubMed Central. Genes, autoimmunity and pathogenesis of rheumatic heart disease
5
PubMed Central. Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies
6
PubMed Central. Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy
7
PubMed Central. Chronic Mitral Valve Fibrosis in Rheumatic Heart Disease: From Immune Trigger to Inflammatory and Mechanical Progression
8
PubMed. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy
9
The Journal of Immunology. Identification of molecules associated with disease progression of autoimmune myocarditis to dilated cardiomyopathy
10
PubMed Central. Giant cell myocarditis
11
PubMed. Management of Patients With Giant Cell Myocarditis: JACC Review Topic of the Week
12
PubMed Central. Libman-Sacks endocarditis in patients with systemic lupus erythematosus with secondary antiphospholipid syndrome
13
The American Journal of Medicine. Libman-Sacks Endocarditis in Systemic Lupus Erythematosus: Prevalence, Associations, and Evolution
14
PubMed. Valvular heart disease in antiphospholipid syndrome
15
Rheumatology. The heart and cardiovascular manifestations in rheumatoid arthritis
16
Inflammation & Allergy-Drug Targets. Myocardial Inflammation in Autoimmune Diseases: Investigation by Cardiovascular Magnetic Resonance and Endomyocardial Biopsy
17
PubMed. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis
18
European Heart Journal. Cardiac involvement in systemic inflammatory diseases
19
PubMed Central. Innovative drug treatments for viral and autoimmune myocarditis
20
PubMed Central. Current Treatment and Immunomodulation Strategies in Acute Myocarditis
21
PubMed. Efficacy of immunosuppressive therapy in myocarditis: A 30-year systematic review and meta analysis
22
PubMed. Rituximab for the Treatment of Refractory Cardiac Sarcoidosis: A Single-Center Experience
23
PubMed Central. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge
24
JCI Insight. Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
25
Cell Reports. PD-1 inhibitor treatment induces immune checkpoint inhibitor-associated myocarditis in A/J mice
26
PubMed Central. Complete heart block in neonatal lupus: a forgotten cause of fetal bradycardia
27
The Journal of Rheumatology. Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals With Autoimmune and Rheumatic Diseases
28
PubMed Central. Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?